Local Liquid drug (LLD) delivery devices have recently emerged as a novel approach to treat peripheral arterial disease. This systemic review aims to identify and evaluate the clinical utility of the most commonly used delivery devices.
Methods:
A systemic review was performed using the Medical Subjects Heading terms of “drug delivery,” “liquid,” “local,” and “cardiovascular disease” in PubMed, Google Scholar, and Scopus.
Results:
Four commonly used delivery devices were identified, including (1) the Bullfrog Micro-Infusion Device, (2) the ClearWay RX Catheter, (3) the Occlusion Perfusion Catheter, and (4) the Targeted Adjustable Pharmaceutical Administration. All have shown to successfully deliver liquid therapeutic into the target lesion and have exhibited favorable safety and efficacy profiles in preclinical and clinical trials. The LLD devices have the ability to treat very long or multiple lesions with a single device, providing a more economical option. The safety profile in LLD clinical studies is also favorable in view of recent concerns regarding adverse events with crystalline-paclitaxel–coated devices.
Conclusion:
There is clear clinical evidence to support the concept of local liquid delivery to treat occlusive arterial disease.
Clinical Impact
The ‘leave nothing behind’ strategy has been at the forefront of the most recent innovations in the field of interventional cardiology and vascular interventions. Although drug coated balloons have overcome limitations associated with plain old balloon angioplasty and peripheral stents, recent safety concerns and cost considerations have impacted their usage. In this review, various liquid drug delivery devices are presented, showcasing their capabilities and success in both preclinical and clinical settings. These innovative liquid delivery devices, capable of targeted delivery and their ability to be re-used for multiple treatment sites, may provide solutions for current unmet clinical needs.
RimamskepSGFavourMDemiladeSA, et al. Peripheral artery disease: a comprehensive updated review. Curr Prob Cardiol. Published online December 11, 2021. doi:10.1016/j.cpcardiol.2021.101082
2.
KokkinidisDGArmstrongEJ.Current developments in endovascular therapy of peripheral vascular disease. J Thorac Dis. 2020;12:1681–1694. doi:10.21037/jtd.2019.12.130
3.
HiramotoJSTeraaMde BorstGJ, et al. Interventions for lower extremity peripheral artery disease. Nat Rev Cardiol. 2018;15:332–350. doi:10.1038/s41569-018-0005-0
4.
SoyoyeDOAbiodunOOIkemRT, et al. Diabetes and peripheral artery disease: a review. World J Diabetes. 2021;12:827–838. doi:10.4239/wjd.v12.i6.827
5.
BaumbachAOberhoffMHerdegC, et al. Local delivery of a low molecular weight heparin following stent implantation in the pig coronary artery. Basic Res Cardiol. 2000;95:173–178. doi:10.1007/s003950050179
6.
OberhoffMNovakSHerdegC, et al. Local and systemic delivery of low molecular weight heparin stimulates the reendothelialization after balloon angioplasty. Cardiovasc Res. 1998;38:751–762. doi:10.1016/s0008-6363(98)00049-2
7.
TeomimDFishbienIGolombG, et al. Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. J Control Release. 1999;60:129–142. doi:10.1016/s0168-3659(99)00071-1
8.
KimWHHongMKKornowskiR, et al. Saline infusion via local drug delivery catheters is associated with increased neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis. 1999;10:629–632. doi:10.1097/00019501-199912000-00012
9.
MitchelJFAzrinMAFramDB, et al. Localized delivery of heparin to angioplasty sites with iontophoresis. Cathet Cardiovasc Diagn. 1997;41:315–323. doi:10.1002/(sici)1097-0304(199707)41:3<315::aid-ccd13>3.0.co;2-m
10.
TepeGZellerTAlbrechtT, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699. doi:10.1056/NEJMoa0706356
11.
OwensCDGasperWJWalkerJP, et al. Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization. J Vasc Surg. 2014;59:1016–1024. doi:10.1016/j.jvs.2013.10.051
12.
RazaviMKDonohoeDD’AgostinoRBJr, et al. Adventitial drug delivery of dexamethasone to improve primary patency in the treatment of superficial femoral and popliteal artery disease: 12-month results from the DANCE clinical trial. JACC Cardiovasc Interv. 2018;11:921–931. doi:10.1016/j.jcin.2017.12.015
13.
HaghighatLAltinSEAttaranRR, et al. Review of the latest percutaneous devices in critical limb ischemia. J Clin Med. 2018;7:82. doi:10.3390/jcm7040082
14.
KwitkowskiVEProwellTMIbrahimA, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist. 2010;15:428–435. doi:10.1634/theoncologist.2009-0178
15.
HawkinsBMHennebryTA.Local paclitaxel delivery for treatment of peripheral arterial disease. Circ Cardiovasc Interv. 2011;4:297–302. doi:10.1161/circinterventions.110.961052
16.
LatifFHennebryTA.Successful revascularization of re-stenosis of lower extremity arteries with localized delivery of paclitaxel. Catheter Cardiovasc Interv. 2008;72:294–298. doi:10.1002/ccd.21598
17.
MaluendaGSizemoreBCRevtyakG, et al. Intracoronary glycoprotein IIb/IIIa inhibitor infusion via a perfusion coronary catheter to decrease thrombus burden: results from the ClearWay™ Multicenter Registry. Cardiovasc Revasc Med. 2013;14:280–283. doi:10.1016/j.carrev.2012.12.006
18.
ShammasNWWeissmanNJCoinerD, et al. Dethrombosis of lower extremity thrombus by local delivery of thrombolysis using ClearWay transcatheter balloon irrigation: a feasibility study. Cardiovasc Revasc Med. 2011;12:350–354. doi:10.1016/j.carrev.2011.06.002
19.
SilvaJARameeSRCohenDJ, et al. Rheolytic thrombectomy during percutaneous revascularization for acute myocardial infarction: experience with the AngioJet catheter. Am Heart J. 2001;141:353–359. doi:10.1067/mhj.2001.112997
20.
BaganPDakhilBLacalP, et al. Acute peripheral arterial occlusion: prospective study evaluating intra-arterial thrombolysis with a micro-porous balloon catheter. J Endovasc Ther. 2013;20:422–426. doi:10.1583/12-4149mr.1
21.
AtighMKTurnerEChristiansU, et al. The use of an occlusion perfusion catheter to deliver paclitaxel to the arterial wall. Cardiovasc Ther. 2017;35. doi:10.1111/1755-5922.12269
22.
BunchFWalkerCKassabE, et al. A universal drug delivery catheter for the treatment of infrapopliteal arterial disease: results from the multi-center first-in-human study. Catheter Cardiovasc Interv. 2018;91:296–301. doi:10.1002/ccd.27176
23.
BunchFNairPAggarwalaG, et al. A universal drug delivery catheter for the treatment of infrapopliteal arterial disease using liquid therapy. Catheter Cardiovasc Interv. 2020;96:393–401. doi:10.1002/ccd.28739
24.
ThiemeMVon BilderlingPPaetzelC, et al. The 24-month results of the Lutonix Global SFA Registry: worldwide experience with Lutonix drug-coated balloon. JACC Cardi-ovasc Interv. 2017;10:1682–1690. doi:10.1016/j.jcin.2017.04.041
25.
SiablisDKitrouPMSpiliopoulosS, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048–1056. doi:10.1016/j.jcin.2014.04.015
26.
ZellerTBaumgartnerIScheinertD, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–1576. doi:10.1016/j.jacc.2014.06.1198
27.
ShishehborM.TCT-177 controlled paclitaxel delivery to the peripheral vasculature with the TAPAS drug delivery system. J Am Coll Cardiol. 2012;60(17_Supplement):B51. doi:10.1016/j.jacc.2012.08.197
28.
RomitiMAlbersMBrochado-NetoFC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975–981. doi:10.1016/j.jvs.2008.01.005
29.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245. doi:10.1161/jaha.118.011245
30.
Rocha-SinghKJDuvalSJaffMR, et al. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. Circulation. 2020;141:1859–1869. doi:10.1161/circulationaha.119.044697
31.
NordanstigJJamesSAnderssonM, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med. 2020;383:2538–2546. doi:10.1056/NEJMoa2005206
32.
SecemskyEAShenCSchermerhornM, et al. Longi-tudinal assessment of safety of femoropopliteal endo-vascular treatment with paclitaxel-coated devices among medi-care beneficiaries: the SAFE-PAD study. JAMA Intern Med. 2021;181:1071–1080. doi:10.1001/jamaintern-med.2021.2738
33.
BehrendtCASedrakyanAPetersF, et al. Editor’s choice - long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg. 2020;59:587–596. doi:10.1016/j.ejvs.2019.12.034
34.
GutierrezJARaoSVJonesWS, et al. Survival and causes of death among veterans with lower extremity revascularization with paclitaxel-coated devices: insights from the Veterans Health Administration. J Am Heart Assoc. 2021;10:e018149. doi:10.1161/jaha.120.018149
35.
SecemskyEABarretteEBockstedtL, et al. Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention. 2021;17:590–598. doi:10.4244/eij-d-20-01018
36.
HataYIidaOItoN, et al. Roles of angioplasty with drug-coated balloon for chronic ischemia in woundhealing. J Endovasc Ther. 2021;28:778–787. doi:10.1177/15266028211025023
37.
GranadaJFStenoienMBuszmanPP, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. 2014;1:e000117. doi:10.1136/openhrt-2014-000117
38.
SpeckUCremersBKelschB, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?Circ Cardiovasc Interv. 2012;5:392–400. doi:10.1161/circinterventions.111.967794
39.
StolzenburgNBreinlJBienekS, et al. Paclitaxel-coated balloons: investigation of drug transfer in healthy and atherosclerotic arteries - first experimental results in rabbits at low inflation pressure. Cardiovasc Drugs Ther. 2016;30:263–270. doi:10.1007/s10557-016-6658-1
40.
KolodgieFDPachecoEYahagiK, et al. Comparison of particulate embolization after femoral artery treatment with IN.PACT Admiral versus Lutonix 035 paclitaxel-coated balloons in healthy swine. J Vasc Interv Radiol. 2016;27:1676–1685. doi:10.1016/j.jvir.2016.06.036
41.
ZhaoHQNikanorovAVirmaniR, et al. Late stent expansion and neointimal proliferation of oversized Nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009;32:720–726. doi:10.1007/s00270-009-9601-z
42.
IidaOTakaharaMSogaY, et al. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions. J Endovasc Ther. 2014;21:485–492. doi:10.1583/14-4721r.1
43.
StampflURadeleffBSommerC, et al. Paclitaxel-induced arterial wall toxicity and inflammation: part 2–long-term tissue response in a minipig model. J Vasc Interv Radiol. 2009;20:1608–1616. doi:10.1016/j.jvir.2009.08.019
44.
UdofotOLinLHThielWH, et al. Delivery of cell-specific aptamers to the arterial wall with an occlusion perfusion catheter. Mol Ther Nucleic Acids. 2019;16:360–366. doi:10.1016/j.omtn.2019.03.005
